ArticleJournal of cosmetic dermatology2025
Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of Q-switched laser combined with intense pulsed light in treating melasma: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Pulsed photobiomodulation reprograms the tumor immune microenvironment to restore local T cell-mediated antitumor immunity.iScience · 2026Article
- Combination Therapy With AOPT Intense Pulsed Light (Dual-Band Vascular Filter) and 1064 nm Nd:YAG Laser for Solitary, Superficial Infantile Hemangioma: A Retrospective Study.Journal of cosmetic dermatology · 2026Article
- Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeTo evaluate the efficacy and underlying mechanism of advanced optimal pulse technology intense pulsed light (AOPT) in low-energy triple-pulse long-width mode (AOPT-LTL) for melasma treatment.
methodsAn in vivo guinea pig model of melasma was established through progesterone injection and ultraviolet B radiation. Three sessions of AOPT-LTL treatment were performed weekly. The mRNA levels of key melanogenic enzymes, inflammatory factors, pro-angiogenic cytokines, and collagenolytic proteases were detected by qRT-PCR. Protein levels of stem cell factor (SCF) and mast cell growth factor receptor (c-KIT) were detected by immunofluorescence staining and Western blotting. Twenty melasma patients were treated with three sessions of AOPT-LTL treatment monthly, evaluated by the Modified Melasma Area and Severity Index (mMASI) and Erythema Index (EI).
resultsIn guinea pigs with melasma, AOPT-LTL treatment effectively mitigated pigmentation and suppressed the expression of key genes involved in melanin production. There was a reduction in mast cell infiltration, decreased expression of inflammatory factors and pro-angiogenic factors, inhibition of angiogenesis, and alleviation of skin photoaging. Furthermore, AOPT-LTL also diminished the expression level of the SCF/c-KIT ligand/receptor pathway, which is closely associated with mast cell proliferation and activation. Consistently, three sessions of AOPT-LTL treatment effectively reduced skin melanin content, erythema severity, as well as the mMASI and EI scores in melasma patients.
conclusionsAOPT-LTL treatment significantly enhances the improvement of melasma by diminishing melanogenesis, inflammation, angiogenesis, mast cell infiltration, and collagen degeneration, potentially through the inhibition of the SCF/c-KIT ligand/receptor pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.